Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

Herrmann, Klaus; Frías, Juan P.; Edelman, Steven V.; Lutz, Karen; Shan, Kevin; Chen, Steven; Maggs, David; Kolterman, Orville G.

doi:10.3810/pgm.2013.05.2635

Cited by 18 publications

(25 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An unattained metabolic control of DM1 has prompted a search for other therapeutic options, like pramlintide or islets transplantation [ 1 – 3 , 10 – 12 ].…”

Section: Discussionmentioning

confidence: 99%

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

Tamez

Garza

et al. 2015

J Diabetes Metab Disord

View full text Add to dashboard Cite

We have evaluated the efficacy of dapagliflozin in patients with type 1 diabetes mellitus (DM1) without adequate control. We expected that adding dapagliflozin to this population on top of their base treatment would lower their HbA1c levels.We conducted a pragmatic, open, 24-week study of treatment with 10 mg of oral dapagliflozin in patients with DM1 and chronic hyperglycemia. We evaluated glycemic control, lipid profile, weight, and insulin dose. Safety was assessed by adverse event reporting.Fasting glucose levels decreased from 176.42 ± 45.33 mg/dL to 139.67 ± 44.42 mg/dL (p = 0.05); although no significant valued was reached, postprandial glucose showed a decreased tendency from 230.25 ± 52.06 mg/dL to 193.83 ± 45.43 mg/dL (p = 0.08). The hemoglobin A1C (HbA1C) level decreased from 9.18 ± 1.02 (77 ± 11.1 mmol/mol) to 8.05 ± 1.09 % (64 ± 11.9 mmol/mol) (p = 0.0156); total cholesterol decreased from 299 ± 12 to 199 ± 7 mg/dL (p = 0.02); triglycerides decreased from 184 ± 15 to 160 ± 11 mg/dL (p = 0.0002), HDL-C decreased from 40 ± 17 to 42 ± 9 mg/dL (p = 0.54); and LDL-C decreased from 187 ± 19 to 170 ± 21 mg/dL (p = 0.049). No adverse events were reported.The beneficial effects of SGLT2 inhibitors on metabolic control and their safety after a 24-week open study demonstrate their potential indication as an adjunctive treatment with insulin in patients with DM1; however, long-term clinical trials should be considered.

show abstract

“…An unattained metabolic control of DM1 has prompted a search for other therapeutic options, like pramlintide or islets transplantation [ 1 – 3 , 10 – 12 ].…”

Section: Discussionmentioning

confidence: 99%

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

Tamez

Garza

et al. 2015

J Diabetes Metab Disord

View full text Add to dashboard Cite

show abstract

“…Зокре-ма показано, що після його підшкірного введення пригнічується апетит у щурів та зменшується кількість спожитої ними їжі [13,14]. А результати обстеження хворих на діабет свідчать, що після застосування аміліну прискорюється відчуття насичення та зменшується надмірна маса тіла [15]. За даними літератури апетит і відчуття наси-чення залежать від концентрації глюкози в крові, тому ми дослідили як вона змінюється у щурів при дії аміліну [16,17].…”

Section: результати та їх обговоренняunclassified

The influence of amylin on the bile acid spectrum in rats

Ip¹,

Sp²,

Za³

et al. 2014

Fiziol Zh

View full text Add to dashboard Cite

show abstract

“…Pramlintide’s side effect profile was favorable, with adverse reactions limited to mild to moderate nausea and headache along with pain at the injection site [ 162 , 163 , 164 , 165 , 166 , 167 , 168 ]. Two recent studies investigating the efficacy of continuous infusion of pramlintide and insulin subcutaneously via a double pump system found this method of treatment to be an effective therapeutic option for patients who have difficulty maintaining optimal glycemic control and/or body weight [ 169 , 170 ].…”

Section: Endocrine Regulation Of Satiety and Energy Homeostasismentioning

confidence: 99%

Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy

Merlino¹,

Blomain²,

Aing³

2014

JCM

View full text Add to dashboard Cite

In recent years, the obesity epidemic has developed into a major health crisis both in the United States as well as throughout the developed world. With current treatments limited to expensive, high-risk surgery and minimally efficacious pharmacotherapy, new therapeutic options are urgently needed to combat this alarming trend. This review focuses on the endogenous gut-brain signaling axes that regulate appetite under physiological conditions, and discusses their clinical relevance by summarizing the clinical and preclinical studies that have investigated manipulation of these pathways to treat obesity.

show abstract

Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

Abstract: www.ClinicalTrials.gov identifiers: NCT00042458, NCT00108004.

Cited by 18 publications

References 29 publications

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

The influence of amylin on the bile acid spectrum in rats

Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy

Contact Info

Product

Resources

About